User login
Key clinical point: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) led to consistent reduction in migraine days throughout the menstrual cycle (perimenstrual and non-perimenstrual days), thereby supporting their prophylactic use in women with menstrual migraine.
Major finding: No significant association was observed between menstrual window and CGRP mAb treatment effect (P = .726), indicating similar reductions in migraine days during the menstrual window and the remainder of the menstrual cycle (odds ratio 0.44; 95% CI 0.38-0.51).
Study details: This post hoc analysis of a single-arm study included 174 patients with migraine treated with either erenumab or fremanezumab for 6 months, and evaluated the effects of anti-CGRP mAb on perimenstrual and non-perimenstrual migraine days in 45 of 174 women with available data on migraine days during ≥3 menstrual cycles.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Verhagen IE et al. Both perimenstrual and non-perimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies. Eur J Neurol. 2023 (Mar 20). Doi: 10.1111/ene.15794
Key clinical point: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) led to consistent reduction in migraine days throughout the menstrual cycle (perimenstrual and non-perimenstrual days), thereby supporting their prophylactic use in women with menstrual migraine.
Major finding: No significant association was observed between menstrual window and CGRP mAb treatment effect (P = .726), indicating similar reductions in migraine days during the menstrual window and the remainder of the menstrual cycle (odds ratio 0.44; 95% CI 0.38-0.51).
Study details: This post hoc analysis of a single-arm study included 174 patients with migraine treated with either erenumab or fremanezumab for 6 months, and evaluated the effects of anti-CGRP mAb on perimenstrual and non-perimenstrual migraine days in 45 of 174 women with available data on migraine days during ≥3 menstrual cycles.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Verhagen IE et al. Both perimenstrual and non-perimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies. Eur J Neurol. 2023 (Mar 20). Doi: 10.1111/ene.15794
Key clinical point: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) led to consistent reduction in migraine days throughout the menstrual cycle (perimenstrual and non-perimenstrual days), thereby supporting their prophylactic use in women with menstrual migraine.
Major finding: No significant association was observed between menstrual window and CGRP mAb treatment effect (P = .726), indicating similar reductions in migraine days during the menstrual window and the remainder of the menstrual cycle (odds ratio 0.44; 95% CI 0.38-0.51).
Study details: This post hoc analysis of a single-arm study included 174 patients with migraine treated with either erenumab or fremanezumab for 6 months, and evaluated the effects of anti-CGRP mAb on perimenstrual and non-perimenstrual migraine days in 45 of 174 women with available data on migraine days during ≥3 menstrual cycles.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Verhagen IE et al. Both perimenstrual and non-perimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies. Eur J Neurol. 2023 (Mar 20). Doi: 10.1111/ene.15794